EMCIP
ALNY icon

Ewing Morris & Co Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ewing Morris & Co Investment Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,440
Closed -$470K – 95
2025
Q2 		$470K Buy
+1,440
New +$398K 0.21% 73

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ewing Morris & Co Investment Partners's ALNY Position: Q3 2025 in Review

Ewing Morris & Co Investment Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 1,440 shares — an estimated $470K sold.

Ewing Morris & Co Investment Partners first reported a position in ALNY in Q2 2025 and held it in 1 quarter. The position peaked at $470K in Q2 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Ewing Morris & Co Investment Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ewing Morris & Co Investment Partners sold 1,440 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $470K.
  • Ewing Morris & Co Investment Partners first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Ewing Morris & Co Investment Partners's Alnylam Pharmaceuticals position peaked at $470K in Q2 2025.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Ewing Morris & Co Investment Partners's 13F filing for Q3 2025, filed 14 Nov 2025.